Key result
Elevated high-sensitivity cardiac troponin I predicted a higher incidence of major adverse cardiovascular events in patients with suspected coronary microvascular dysfunction.
Why the study?
The study was conducted to examine the distribution of hs-cTnI and myoglobin in patients with suspected coronary microvascular dysfunction.
Does elevated hs-cTnI predict impaired CFR and MACE in patients with suspected coronary microvascular dysfunction?
Cohort (n=1,524)
Does elevated hs-cTnI predict impaired CFR and MACE in patients with suspected coronary microvascular dysfunction?
Answers are grounded in this paper and cite their sources.
Elevated hs-cTnI is an independent predictor of worse microvascular dysfunction and adverse cardiovascular outcomes in patients with suspected coronary microvascular dysfunction.
To examine distribution of high-sensitivity cardiac troponin I (hs-cTnI) and myoglobin in patients with suspected coronary microvascular dysfunction (CMD). This study included consecutive patients with chest pain suspected of CMD. Baseline hs-cTnI, myoglobin, and coronary flow reserve (CFR) were assessed. Patients were categorized by hs-cTnI level using the 99th percentile cutoff (28 ng/L). Multivariable regression analyses evaluated associations with impaired CFR and major adverse cardiovascular events (MACE). Among 1,524 patients, 412 (27.0%) had elevated hs-cTnI. Higher hs-cTnI levels were inversely correlated with CFR. Each 10 ng/L increase in hs-cTnI was independently associated with impaired CFR (adjusted odds ratio 1.32). During a follow-up of 24.5 months, elevated hs-cTnI predicted a higher incidence of MACE (adjusted hazard ratio 2.35). Myoglobin alone was not predictive, but concurrent elevation with hs-cTnI further increased MACE risk. Elevated hs-cTnI is independently associated with worse microvascular dysfunction and adverse outcomes in suspected CMD.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cohort in Suspected coronary microvascular dysfunction (n=1,524). Elevated high-sensitivity cardiac troponin I (≥28 ng/L) vs. Non-elevated hs-cTnI (<28 ng/L) was evaluated on Major adverse cardiovascular events (MACE) (HR 2.35). Elevated high-sensitivity cardiac troponin I predicted a higher incidence of major adverse cardiovascular events in patients with suspected coronary microvascular dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: